Company
Avalyn
Targeted therapies for rare lung diseases
Also known as Avalyn Pharma, Avalyn Pharma Inc.
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Legal name
- Avalyn Pharma Inc.
- avalynpharma.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
Avalyn is a clinical-stage biotech company developing inhaled therapies to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases.
Funding snapshot
- Total raised
- $245MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $189M2023-09-22
Funding rounds
- Round, 2023
- $189M2023-09-22, SEC form D sold, 26 investors
- Round, 2020
- $35.5M2020-04-24, SEC form D sold, 8 investors
- Round, 2017
- $18.2M2017-03-13, SEC form D sold, 46 investors
- Round, 2011
- $2.2M2011-10-23, SEC form D sold, 41 investors
Products
- Web
- AP01
- Web
- AP02
- Web
- AP03
Loading relationship preview